<DOC>
	<DOCNO>NCT00005988</DOCNO>
	<brief_summary>RATIONALE : Bone marrow transplantation may able replace immune cell destroy chemotherapy radiation therapy use kill tumor cell . Sometimes transplanted cell make immune response body 's normal tissue . Treatment donor bone marrow patient 's white blood cell monoclonal antibody may prevent happen . PURPOSE : Phase I trial study effectiveness bone marrow transplantation specially treat bone marrow treat patient hematologic cancer respond previous therapy .</brief_summary>
	<brief_title>Bone Marrow Transplantation With Specially Treated Bone Marrow Treating Patients With Hematologic Cancer That Have Not Responded Previous Therapy</brief_title>
	<detailed_description>OBJECTIVES : I . Determine patient refractory , high risk hematologic malignancy bone marrow failure receive HLA haploidentical bone marrow treat anti-B7 antibody normal engraftment . II . Determine patient free hyperacute graft versus host disease ( GVHD ) , define grade D GVHD first 10 posttransplant day , treated regimen . III . Determine patient acceptable incidence life threaten grade D GHVD first 50 posttransplant day follow treatment regimen . IV . Determine safety tolerability treatment regimen patient population . OUTLINE : This multicenter study . Patients undergo leukapheresis collect white blood cell incubate donor bone marrow cell presence anti-B7.1 anti-B7.2 antibody 36 hour . Patients receive total body irradiation twice daily day -6 -3 , cyclophosphamide IV daily day -2 -1 , methylprednisolone IV every 12 hour total 4 dos day -2 0 . Patients infuse treated donor bone marrow day 0 . Patients receive methotrexate IV day 1 , 3 , 6 , 11 leucovorin calcium IV 24 hour dose methotrexate every 6 hour 3-8 dos time . Patients also receive cyclosporine IV orally twice daily day -2 100 . Patients follow every 2 month 1 year . PROJECTED ACCRUAL : A total 20 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Age ≤40 year . Diagnoses—patients follow hematologic malignancy bone marrow failure syndrome : Acute myelogenous leukemia—induction failure , relapse , second great complete remission ( CR ) Acute lymphocytic leukemia—induction failure , relapse , second great CR , first CR ( 9 ; 22 ) , ( 8 ; 14 ) , ( 4 ; 11 ) NonHodgkin 's lymphoma ( intermediate high grade ) fail achieve CR least two induction regimen , relapse , second great CR Multiple myeloma poor prognostic feature ( elevate 02 microglobulin high label index ) Hodgkin 's disease relapse fail achieve CR two chemotherapy regimen Congenital acquire bone marrow failure poorly responsive intolerant current therapy Myelodysplastic syndrome subtypes except refractory anemia ( RA ) Patient haploidentical family member meet medical criterion donation . Eligibility transplant type : Patient consider likely clinical deterioration rapid disease progression unrelated donor search , Patient already unproductive donor search Patient ineligible refuse autologous transplant Adequate renal hepatic function age : Serum creatinine &lt; 2 x ULN Alanine aminotransferase ( ALT , SGPT ) x ULN Aspartate aminotransferase ( AST , SGOT ) x ULN Total bilirubin 5_2 x ULN except bilirubin elevate due Gilbert 's syndrome hemolytic anemia Adequate cardiac pulmonary function age . ECOG Performance Status 0 , 1 , 2 Lansky performance scale &gt; 50 % patient &lt; 16 year age . Voluntary witness write informed consent . Children ask assent appropriate . The patient , female , must postmenopausal , premenarcheal , sterile , patient childbearing potential , must practice method birth control consider effective medically acceptable investigator minimum 1 month prior study entry least 2 month study end . Patient must undergo successful leukapheresis obtain adequate antigen present cell . Any patient enters study relapse state , evidence end organ ( pulmonary , renal , hepatic ) toxicity , recent recovery infection , may potentially little benefit protocol , must his/her eligibility status discuss Principal Investigator . Patient must life expectancy least 12 week . Exclusion Criteria Eligibility transplant type : Patient family donor match single antigen mismatch HLAA , HLAB , HLADR , HLADQ . Donorrecipient match must evaluate via phenotype genotype . Patient available unrelated donor match HLAA , HLAB , HLADR . Donorrecipient match must evaluate via phenotype genotype . Active uncontrolled infection ( continued positive blood soft tissue culture despite appropriate antibiotic treatment ) Positive 13HCG female childbearing potential Evidence HIV infection know HIV positive serology Any prior bone marrow transplant A peripheral blood differential count time leukapheresis great 25 % blast . This exclusion criterion valid first four patient enrol . Patients Fanconi 's anemia</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage I childhood lymphoblastic lymphoma</keyword>
	<keyword>stage II childhood lymphoblastic lymphoma</keyword>
	<keyword>stage III childhood lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>childhood diffuse large cell lymphoma</keyword>
	<keyword>childhood immunoblastic large cell lymphoma</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage I adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult lymphoblastic lymphoma</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>graft versus host disease</keyword>
	<keyword>stage I childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage I childhood large cell lymphoma</keyword>
	<keyword>stage II childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage II childhood large cell lymphoma</keyword>
	<keyword>stage III childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage III childhood large cell lymphoma</keyword>
	<keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage IV childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>refractory cytopenia multilineage dysplasia</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>